Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

COCP vs PRPO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRPO Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–5 Matrix Metrics)

PRPO Overall Winner 6-Pillar Tally: COCP 0 – 5 PRPO (1 Tie) Matrix Metrics: COCP 5 – 5 PRPO

As of Nov 16, 2026, Precipio, Inc. (PRPO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas PRPO carries 32.2/100 (SELL) at $20.39 (15.4x Forward P/E, -5.3% operating margin).

  • Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. PRPO 32.2/100 SELL), PRPO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-5.3% vs. -3063.6% operating margin) and revenue trajectory (+8.3% vs. +26.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCP vs PRPO
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $1.00 · SMA50: $1.08
PRPO NASDAQ Head-to-Head Winner
Precipio, Inc. Common Stock
Laboratory Analytical Instruments
$20.39
-7.86% 1D
Market Cap $40.2M
TTM Revenue $28M
Forward P/E 15.4x
Beta / 30D Vol 1.19β · 95% Vol
Unified Composite Score
32.2 / 100 SELL
Tech 5.0 Fund 31.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.1 · SMA20: $20.38 · SMA50: $22.83

6-Pillar Scorecard Institutional Category Breakdown (COCP 0 – 5 PRPO)

Columns: Metric · COCP · PRPO
1. Valuation Multiples PRPO
Forward P/E N/M 15.4x
Trailing P/E N/M 15.4x
PEG Ratio N/M N/M
EV / Revenue 49.7x 1.4x
2. Growth & Scale PRPO
Revenue Growth (YoY) +26.9% +8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $330,000 $28M
Market Cap $19.6M $40.2M
3. Profitability & Quality PRPO
Gross Margin N/A 44.6%
Operating Margin -3063.6% -5.3%
Net Profit Margin 0.0% -4.1%
Return on Equity (ROE) -311.7% -8.0%
4. Balance Sheet & Cash Flow PRPO
Cash Generation (TTM) -$7.6M -$56,000 EBITDA
Cash Flow Margin N/A -0.2% EBITDA Mgn
Net Cash / Leverage $3.3M Net Cash $8.29 Book/Sh · -8.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat PRPO
OpEx & R&D Intensity N/A 49.9% of Rev ($14M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCP (5) vs PRPO (5)
Institutional Metric COCP PRPO Criterion Row Edge
Market Capitalization
Scale
$19.6M $40.2M Larger Scale PRPO
Trailing P/E Ratio
Valuation
N/M 15.4x Lower Multiple PRPO
Forward P/E Ratio
Valuation
N/M 15.4x Lower Multiple PRPO
Revenue Growth (YoY)
Growth
+26.9% +8.3% Higher Growth COCP
Operating Margin (TTM)
Profitability
-3063.6% -5.3% Higher Margin PRPO
Net Profit Margin
Profitability
0.0% -4.1% Higher Margin COCP
Return on Equity (ROE)
Capital Efficiency
-311.7% -8.0% Higher ROE PRPO
52-Week Range Position
Momentum
19% ($1–$2) 16% ($18–$34) Stronger Trend COCP
Beta / 30D Volatility
Risk Regime
1.04β · 54% Vol 1.19β · 95% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 32.2 / 100 (SELL) Higher Composite COCP
Trailing 12M Revenue (USD)
Operating Scale
$330,000 $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 49.7x EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($3.3M Net Cash) -$56,000 EBITDA ($8.29 Book/Sh · -8.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +2.6 pp
COCP: -2.01% · PRPO: -4.61%
3M Horizon COCP +9.97 pp
COCP: -7.45% · PRPO: -17.42%
6M Horizon COCP +2.96 pp
COCP: -15.3% · PRPO: -18.26%
1Y Horizon PRPO +7.42 pp
COCP: -2.96% · PRPO: +4.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on COCP vs PRPO. Trailing 12-month operating profitability (COCP -3063.6% vs PRPO -5.3%) and valuation multiples (COCP N/M vs PRPO 15.4x Forward P/E) are benchmarked directly in Pillar 4 below.

COCP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$330,000
Gross MarginN/A
Op. Margin-3063.6%
ROE / Fwd P/E-311.7% · N/M
PRPO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin44.6%
Op. Margin-5.3%
ROE / Fwd P/E-8.0% · 15.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRPO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PRPO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRPO Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $40.2M market capitalization and -5.3% operating margin.
OpEx & R&D Reinvestment 49.9% of Rev ($14M)
90D Engineering Disclosures 0 Published

Investor FAQ COCP vs PRPO Key Questions & Quantitative Answers

As of Nov 16, 2026, Precipio, Inc. (PRPO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas PRPO carries 32.2/100 (SELL) at $20.39 (15.4x Forward P/E, -5.3% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. PRPO 32.2/100 SELL), PRPO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-5.3% vs. -3063.6% operating margin) and revenue trajectory (+8.3% vs. +26.9% YoY).

PRPO leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with PRPO at +8.3% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (44.6% gross margin, -5.3% operating margin). On trailing 12-month operating scale, COCP generates $330,000 in USD-normalized revenue versus $28M for PRPO. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus 49.9% of Rev ($14M) (0 disclosures) for PRPO.

PRPO screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin), whereas PRPO trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-0.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus PRPO (-8.0% ROE) capital efficiency.

In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk). By comparison, PRPO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 95% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.